Skip to content
Abierto
Menu

Justification, first published as award notice

J&A ERVEBO

75A50124C00057

Office of Assistant Secretary for Preparedness and Response, Barda - Aspr / Daappo / Barda DCMA. Pharmaceutical Preparation Manufacturing.

View on SAM.govMarkdown

Awarded

Merck Sharp & Dohme LLC

$156,033,983.00 obligated so far on USAspending, September 27, 2024, contract 75A50124C00057

Description

As published on SAM.gov.

This is a Justification & Approval (J&A) in accordance with FAR 6.302-1 Only one responsible source and no other supplies or services will satisfy agency requirements. This acquisition will allow BARDA to invest Project Bioshield funds for the procurement of a FDA licensed Zaire ebolavirus vaccine, ERVEBO; final drug product stored in vendor managed inventory (VMI) and; development of an updated manufacturing process.

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

Recipient
Merck Sharp & Dohme LLC
UEI
FCFDA78HKKG2
CAGE
6B2S4
Vendor location
Rahway, NJ
Contract
75A50124C00057, definitive contract
Obligated
$156,033,983.00, potential $173,814,205
Actions
4 between September 27, 2024 and September 10, 2026
Competition
Not Competed, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Ervebo Procurement
Match
award number 75A50124C00057 equals the contract number; same awarding office 75A501 (high confidence)
Record
USAspending award page

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. October 2, 2024

    Award notice, originally special notice

    Notice of Award: ERVEBO

    Awarded to MERCK SHARP & DOHME LLC Rahway for $174,606,743. SAM.gov, notice 419cac0d2a1141f3ba572d6897e1b92e

  2. October 7, 2024

    Justification

    SAM.gov, notice 67fd4ef2b71641f5b7c06049ff893a19

Points of contact

Also open from this buyer